Holding(s) in Company TR-1: Standard form for notification of major holdings
TR-1: Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS(to be sent to the relevant issuerandto the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Verona Pharma plc 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)Non-UK issuer 2. Reason for the notification(please...
LONDON,
(informazione.it - comunicati stampa - salute e benessere)
TR-1: Standard form for notification of major holdings
| NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i | ||||||
| 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: | Verona Pharma plc | |||||
| 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) | ||||||
| Non-UK issuer | ||||||
| 2. Reason for the notification (please mark the appropriate box or boxes with an “X”) | ||||||
| An acquisition or disposal of voting rights | X | |||||
| An acquisition or disposal of financial instruments | ||||||
| An event changing the breakdown of voting rights | ||||||
| Other (please specify)iii: | ||||||
| 3. Details of person subject to the notification obligationiv | ||||||
| Name | Arix Bioscience plc | |||||
| City and country of registered office (if applicable) | ||||||
| 4. Full name of shareholder(s) (if different from 3.)v | ||||||
| Name | ||||||
| City and country of registered office (if applicable) | ||||||
| 5. Date on which the threshold was crossed or reachedvi: | 16 January 2020 | |||||
| 6. Date on which issuer notified (DD/MM/YYYY): | 16 January 2020 | |||||
| 7. Total positions of person(s) subject to the notification obligation | ||||||
| % of voting rights attached to shares (total of 8. A) |
% of voting rights through financial instruments (total of 8.B 1 + 8.B 2) |
Total of both in % (8.A + 8.B) |
Total number of voting rights of issuervii | |||
| Resulting situation on the date on which threshold was crossed or reached | 3.2% | 3.2% | 105,326,638 | |||
| Position of previous notification (if applicable) |
4.5% | 4.5% | ||||
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii |
|||||||||
| A: Voting rights attached to shares | |||||||||
| Class/type of shares ISIN code (if possible) |
Number of voting rightsix | % of voting rights | |||||||
| Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) |
Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
||||||
| GB00BYW2KH80 | 1,290,352 | 2,110,000 | 1.2% | 2.0% | |||||
| SUBTOTAL 8. A | 3,400,352 | 3.2% | |||||||
| |
|||||||||
| B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) | |||||||||
| Type of financial instrument | Expiration datex |
Exercise/ Conversion Periodxi |
Number of voting rights that may be acquired if the instrument is exercised/converted. |
% of voting rights | |||||
| SUBTOTAL 8. B 1 | |||||||||
| |
|||||||||
| B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) | |||||||||
| Type of financial instrument | Expiration datex |
Exercise/ Conversion Period xi |
Physical or cash settlementxii |
Number of voting rights | % of voting rights | ||||
| SUBTOTAL 8.B.2 | |||||||||
| 9. Information in relation to the person subject to the notification obligation
(please mark the applicable box with an “X”) |
|||||
| Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii | |||||
| Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary) |
|||||
| Namexv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | ||
| Arix Bioscience plc | 3.2% | 3.2% | |||
| Arix Bioscience Holdings Limited | 1.2% directly | 1.2% directly | |||
| Arthurian Life Sciences SPV GP Limited for and on behalf of The Wales Life Sciences Investment Fund LP | 2.0% indirectly | 2.0% indirectly | |||
| 10. In case of proxy voting, please identify: | |||||
| Name of the proxy holder | |||||
| The number and % of voting rights held | |||||
| The date until which the voting rights will be held | |||||
| 11. Additional informationxvi | |||||
| Place of completion | London, United Kingdom |
| Date of completion | 17 January 2020 |
 in Company TR-1: Standard form for notification of major holdings)
Ufficio Stampa
Nasdaq GlobeNewswire (Leggi tutti i comunicati)
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti
